Abstract Library

#1699 Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization be Evaluated at 60 Seconds or At 120 Seconds?

Introduction: The selective arterial secretagogue injection (SASI) test is considered indispensable for an accurate insulinoma localization. The optimal timing of post-injection evaluation has not been established yet, as some studies recommend 60 seconds [SASI (60 sec)] while others support 120 seconds [SASI (120 sec)].

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ueda K, Kawabe K, Lee L, Tachibana Y, Fujiyama T,

Keywords: insulinoma, selective arterial secretagogue injection test, localization, insulin,

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,

#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms

Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lee L

Authors: Lee L, Ito T, Kawabe K, Otsuka T, Nakamura M,

Keywords: Somatostatin receptor, dopamine receptor, SSTR2, D2R,